Endothelin receptor antagonists for pulmonary arterial hypertension: an overview.

Article Details

Citation

Copy to clipboard

Raja SG

Endothelin receptor antagonists for pulmonary arterial hypertension: an overview.

Cardiovasc Ther. 2010 Oct;28(5):e65-71. doi: 10.1111/j.1755-5922.2010.00158.x.

PubMed ID

20406243 [ View in PubMed

]

Abstract

The last decade has seen major advances in the pharmacotherapy of pulmonary arterial hypertension (PAH). One of these advances has been the discovery of endothelin receptor antagonists (ERAs). ERAs are a class of potent vasodilators and antimitotic substances, which could specifically dilate and remodel pulmonary arterial system, and have been proposed as an alternative to traditional therapies for PAH. Current available evidence suggests that ERAs improve exercise capacity, functional status, pulmonary hemodynamics, and delay the time to clinical worsening for patients with PAH. This review attempts to provide an overview of the pharmacology, therapeutic benefits, and safety profile of ERAs in patients with PAH.

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Sitaxentan	Cytochrome P450 2C19	Protein	Humans	Unknown	Inhibitor	Details